iJRASET
International Journal For Research in Applied Science and Engineering Technology



INTERNATIONAL JOURNAL FOR RESEARCH

IN APPLIED SCIENCE & ENGINEERING TECHNOLOGY

Volume: 13 **Issue:** IV **Month of publication:** April 2025

DOI: https://doi.org/10.22214/ijraset.2025.69259

www.ijraset.com

Call: 08813907089 | E-mail ID: ijraset@gmail.com

International Journal for Research in Applied Science & Engineering Technology (IJRASET)
ISSN: 2321-9653; IC Value: 45.98; SJ Impact Factor: 7.538
Volume 13 Issue IV Apr 2025- Available at www.ijraset.com

Lipid Based Nano Carriers in Cancer Therapy

Kalyani Nerkar[1], Vedant Rane[2], Mohini Chaudhari[3], Prof. Rahul S. Patil[4]
NTVS Institute of Pharmacy, Nandurbar

Abstract: ***Cancer remains a leading cause of mortality worldwide, and conventional therapies often face limitations such as non-specificity, systemic toxicity, and multidrug resistance. Lipid-based nanocarriers have emerged as a promising strategy for targeted cancer therapy due to their biocompatibility, ability to encapsulate both hydrophilic and hydrophobic drugs, and potential for surface modification to enhance targeting. This review highlights various types of lipid-based nanocarriers, including liposomes, solid lipid nanoparticles, and nanostructured lipid carriers, focusing on their design, mechanisms of targeting, and therapeutic applications. Emphasis is placed on advances in active and passive targeting approaches, current clinical status, and the challenges that need to be addressed for successful translation into clinical practice. The integration of lipid-based nanocarriers with emerging technologies such as stimuli-responsive systems and personalized medicine holds great potential to revolutionize cancer treatment.***

Keywords: Lipid-based nanocarriers, Targeted drug delivery, Cancer therapy, Liposomes, Nanostructured lipid carriers, Tumor targeting

I. INTRODUCTION

Cancer is one of the most complex and fatal diseases globally, responsible for millions of deaths each year. Despite significant advances in diagnosis and treatment, effective and safe delivery of anticancer agents remains a major challenge. Traditional chemotherapeutic regimens are often limited by poor specificity, systemic toxicity, low bioavailability, and the development of multidrug resistance (MDR). These limitations not only compromise therapeutic efficacy but also lead to severe side effects, significantly affecting patients' quality of life. Therefore, the development of novel drug delivery systems that can selectively target tumor tissues while minimizing off-target effects has become a central focus in oncology research.


In recent years, nanotechnology has emerged as a transformative tool in medicine, particularly in the field of drug delivery. Among various nanocarrier systems, lipid-based nanocarriers have gained substantial attention due to their unique physicochemical properties, biocompatibility, biodegradability, and ability to encapsulate both hydrophilic and hydrophobic drugs. These nanocarriers mimic biological membranes and are less likely to provoke immune responses, making them ideal candidates for systemic administration.

Lipid-based nanocarriers encompass a diverse range of formulations, including liposomes, solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), lipid-polymer hybrid nanoparticles, and micelles. Each of these systems offers distinct advantages in terms of drug loading, release kinetics, stability, and targeting potential. One of the most promising aspects of these carriers is their ability to achieve targeted drug delivery through both passive and active targeting mechanisms. Passive targeting exploits the enhanced permeability and retention (EPR) effect observed in tumor vasculature, while active targeting involves surface modification of nanocarriers with ligands (e.g., antibodies, peptides, or aptamers) that can specifically recognize tumor-associated markers.

Moreover, lipid-based nanocarriers can be engineered to respond to specific stimuli such as pH, temperature, enzymes, or redox gradients within the tumor microenvironment, thereby ensuring controlled and site-specific drug release. Such **stimuli-responsive systems** further enhance therapeutic outcomes and reduce systemic toxicity.

This review aims to provide a comprehensive overview of lipid-based nanocarriers in the context of targeted cancer therapy. It discusses various types of lipid-based nanocarriers, their design principles, mechanisms of drug targeting, and recent advancements in their clinical applications. Additionally, the review addresses current challenges, including formulation stability, scale-up, regulatory hurdles, and clinical translation, while highlighting future perspectives in the integration of lipid-based nanocarriers with personalized and precision medicine.[1,2]

©IJRASET: All Rights are Reserved



A. Liposome Design for Cancer Therapy

Liposomes are spherical vesicles composed of one or more phospholipid bilayers enclosing an aqueous core. Their structural versatility allows for the encapsulation of a wide range of therapeutic agents, including hydrophilic drugs (in the core) and hydrophobic drugs (within the lipid bilayer). This dual capability makes them particularly effective for complex chemotherapeutic regimens.

The design of liposomes for cancer therapy typically involves the following key components:

- Phospholipids: Natural or synthetic lipids (e.g., phosphatidylcholine) form the bilayer structure. The choice of lipid affects membrane fluidity, stability, and drug release profile.
- Cholesterol: Often incorporated to modulate membrane rigidity and improve the structural integrity of liposomes in systemic circulation.
- Surface Modification: PEGylation (coating with polyethylene glycol) is used to form “stealth liposomes” that evade immune detection and prolong circulation time. Additionally, ligands such as folic acid, transferrin, or monoclonal antibodies can be attached to enhance active targeting.
- Size and Charge: Liposomes are generally sized between 50–200 nm for optimal tumor penetration via the Enhanced Permeability and Retention (EPR) effect. Surface charge also influences biodistribution and cellular uptake.

The optimization of these parameters is crucial for enhancing tumor selectivity, minimizing off-target effects, and maximizing therapeutic efficacy.

II. MECHANISMS OF TARGETING

Lipid-based nanocarriers exploit two primary targeting mechanisms:

A. Passive Targeting

Passive targeting leverages the anatomical and physiological abnormalities of tumor vasculature. Tumors often exhibit leaky blood vessels and poor lymphatic drainage, which allows nanoparticles (typically 100–200 nm in size) to accumulate preferentially in the tumor tissue—a phenomenon known as the EPR effect. Lipid-based nanocarriers can be engineered to remain stable in circulation and take advantage of this effect to concentrate at tumor sites.

B. Active Targeting

Active targeting involves the modification of nanocarrier surfaces with **ligands** that recognize and bind to specific receptors overexpressed on cancer cells or tumor endothelium. Common targets include:

- Folic acid receptor (highly expressed in ovarian, breast, and lung cancers)
- HER2 receptor (breast cancer)
- Transferrin receptor (leukemia, lymphoma)
- Integrins (e.g., αvβ3) (angiogenic blood vessels in tumors)

Upon receptor-ligand binding, nanocarriers are internalized via receptor-mediated endocytosis, enhancing intracellular drug delivery and reducing systemic toxicity.[3,4]

III. CLINICAL CASE STUDIES AND APPLICATIONS

Several lipid-based nanocarriers have advanced from preclinical research into clinical trials and even commercial use, validating their therapeutic potential. A few notable examples include:

1) Doxil® (pegylated liposomal doxorubicin): The first FDA-approved liposomal anticancer drug. It offers improved pharmacokinetics and reduced cardiotoxicity compared to conventional doxorubicin. Indicated for ovarian cancer, multiple myeloma, and Kaposi's sarcoma.
2) DaunoXome® (liposomal daunorubicin): Approved for HIV-associated Kaposi's sarcoma. It improves drug accumulation in tumor tissue and reduces toxicity.
3) Myocet®: A non-pegylated liposomal doxorubicin used in combination with cyclophosphamide for metastatic breast cancer treatment in Europe and Canada.

Ongoing clinical trials are exploring lipid-based formulations for a variety of cancers, including glioblastoma, pancreatic cancer, and non-small cell lung cancer. Many of these trials focus on incorporating targeting ligands or stimuli-responsive elements to further refine specificity and therapeutic outcomes.

A. *Stimuli-Responsive Lipid Nanocarriers*

One of the most promising advancements in the field of targeted cancer therapy is the development of stimuli-responsive lipid nanocarriers. These systems are intelligently designed to respond to specific internal (endogenous) or external (exogenous) stimuli within the tumor microenvironment (TME) or applied externally to the patient. This enables site-specific drug release, minimizes premature leakage during circulation, and enhances therapeutic efficiency while reducing systemic toxicity.

Cancerous tissues possess distinct biological and physicochemical properties compared to normal tissues, which can be exploited to design nanocarriers that release their payloads only under specific conditions.[5,6]

B. *pH-Sensitive Lipid Nanocarriers*

Tumor tissues often exhibit a slightly acidic extracellular pH (6.5–6.9) due to the high rate of glycolysis and poor perfusion, whereas normal tissues maintain a near-neutral pH (~7.4). Additionally, intracellular compartments such as endosomes and lysosomes are even more acidic (pH 5–6).

pH-sensitive lipid nanocarriers are engineered to remain stable at physiological pH but become destabilized in acidic environments, triggering the release of their encapsulated drug. This is achieved by:

- Using pH-sensitive lipids (e.g., phosphatidylethanolamine) that destabilize at low pH.
- Incorporating acid-labile linkers (e.g., hydrazone, imine) between the drug and lipid/carrier.
- Designing lipid bilayers that transition to hexagonal phases in acidic conditions, disrupting the membrane and releasing the drug.

Such systems ensure drug release specifically at the tumor site or within cancer cells after endocytosis, enhancing intracellular delivery.

IV. TEMPERATURE-SENSITIVE LIPID NANOCARRIERS

Tumors often exhibit a slightly elevated temperature due to inflammation and abnormal vasculature, but for more precise control, external heating (e.g., local hyperthermia, infrared light, or ultrasound) is often used to trigger temperature-sensitive nanocarriers.

These carriers are designed using thermo-responsive lipids or polymers that undergo a phase transition at a specific temperature (typically 39–42°C), which causes disruption of the lipid bilayer and rapid drug release.

Example: ThermoDox®, a temperature-sensitive liposomal formulation of doxorubicin, releases its drug cargo upon mild hyperthermia and is currently in clinical trials for liver cancer and breast cancer.

This strategy allows for temporal and spatial control of drug release, especially when combined with imaging-guided hyperthermia.

©IJRASET: All Rights are Reserved | SJ Impact Factor 7.538 | ISRA Journal Impact Factor 7.894 |

V. ENZYME-SENSITIVE LIPID NANOCARRIERS

Certain proteolytic enzymes are overexpressed in the tumor microenvironment, such as:

- Matrix metalloproteinases (MMPs) – involved in tumor invasion and metastasis.
- Cathepsins – lysosomal enzymes upregulated in many cancers.
- Phospholipases – which degrade phospholipids in tumor-associated inflammation.

Lipid nanocarriers can be tailored to degrade or undergo structural changes upon contact with these enzymes. For example:

- Peptide linkers cleaved by MMPs** can release the active drug or cause structural collapse of the carrier.
- Lipid bilayers incorporating enzyme-cleavable prodrugs become activated specifically in the TME.

This enzyme-responsive strategy enhances specificity and reduces off-target activation, especially in metastatic or invasive tumor types.[7,8]

A. Redox-Sensitive Lipid Nanocarriers

Cancer cells typically exhibit higher intracellular levels of glutathione (GSH) (up to 1000x more than extracellular levels), creating a reducing environment. Redox-sensitive lipid carriers exploit this redox gradient for intracellular drug release.

These nanocarriers often incorporate:

- Disulfide linkages (-S-S-) that remain stable in the bloodstream but are cleaved in the presence of high GSH levels within tumor cells.
- Upon cleavage, the structural integrity of the nanocarrier is disrupted, leading to rapid drug release within the cytoplasm.

Redox-sensitive systems are particularly effective for delivering drugs, genes, or siRNA that require cytoplasmic action, enhancing bioavailability at the intracellular level.

B. Advantages of Stimuli-Responsive Systems

- Improved site-specificity and reduced off-target toxicity
- Enhanced therapeutic index of anticancer agents
- Controlled release profile adapted to tumor biology
- Potential for combination with imaging (theragnostic) and multimodal therapy

VI. DRUG LOADING AND RELEASE MECHANISMS

A. Techniques for Drug Incorporation

Efficient drug loading is a critical parameter influencing the therapeutic performance of lipid-based nanocarriers. Two primary methods are used:

1) Passive Loading

- Drugs are incorporated during nanocarrier formation.
- Works well for hydrophobic drugs (into the lipid bilayer) and hydrophilic drugs (in the aqueous core).
- Simpler but often has low loading efficiency and less control over drug distribution.

2) Active (Remote) Loading

- Uses transmembrane gradients (pH, ion, or ammonia) to drive drug molecules into preformed vesicles.
- Offers high encapsulation efficiency and better drug retention.
  Example: Doxil® uses a pH gradient to actively load doxorubicin.

VII. CONTROLLED/SUSTAINED RELEASE STRATEGIES

Sustained release from lipid nanocarriers improves plasma half-life and reduces dosing frequency. Controlled release is influenced by:

- Lipid composition (fluidity, chain length, saturation)
- Presence of stabilizers (e.g., cholesterol)
- Surface coatings (e.g., PEG)
- Cross-linking or incorporation of stimuli-responsive elements

These strategies ensure a gradual release profile, ideally aligning with the therapeutic window of the encapsulated drug.

©IJRASET: All Rights are Reserved | SJ Impact Factor 7.538 | ISRA Journal Impact Factor 7.894 |

A. *Stability and Release Kinetics*

Drug release kinetics determine how well the drug is protected and how effectively it is delivered. Stability must be evaluated under:

- Physiological conditions (pH 7.4, 37°C)
- Storage (refrigeration, freeze-thaw stability)
- In serum-containing media (to simulate in vivo conditions)

Analyzing in vitro release profiles helps predict in vivo behavior and optimize formulations for maximum therapeutic output.[9,10]

VIII. PRECLINICAL STUDIES AND IN VIVO EVALUATIONS

A. *Animal Models*

Common animal models for evaluating lipid-based nanocarriers include:

- Murine xenograft models: Human cancer cells implanted in immunodeficient mice.
- Syngeneic mouse models: Mouse cancer cells in immunocompetent mice (useful for immunotherapy studies).
- Orthotopic models: Tumor cells implanted at the organ of origin for better tumor microenvironment replication.

These models help in assessing tumor accumulation, systemic toxicity, and overall therapeutic efficacy.

B. *Pharmacokinetics and Biodistribution*

Lipid-based nanocarriers are evaluated for:
Circulation half-life
Area under the curve (AUC)
Volume of distribution (Vd)
Tumor-to-normal tissue accumulation ratio
Advanced imaging techniques (e.g., fluorescence, PET, MRI) are used for real-time biodistribution tracking.

C. *Toxicity and Safety*

Compared to free drugs, lipid nanocarriers significantly reduce:
Hematological toxicity
Cardiomyopathy (e.g., Doxil vs doxorubicin)
Organ-specific accumulation
Toxicology studies include acute, sub-chronic, and chronic toxicity evaluations, including histopathology and blood biochemistry analyses.

IX. CLINICAL TRANSLATION AND REGULATORY ASPECTS

A. *Regulatory Guidelines*

The FDA (U.S.) and EMA (Europe) have frameworks for nanomedicines, but regulatory processes are complex due to:
Diverse formulations
Lack of standardized characterization methods
Concerns about batch-to-batch consistency
Key requirements include:

- Particle size/distribution
- Drug loading and release
- Stability studies
- Biocompatibility and sterility

B. *Scale-Up Challenges*

Transitioning from lab-scale to industrial-scale production is challenging due to:

- Reproducibility issues
- Equipment scalability
- Cost of raw materials (e.g., high-purity lipids)

©IJRASET: All Rights are Reserved | SJ Impact Factor 7.538 | ISRA Journal Impact Factor 7.894 |

C. Sterilization and Stability

Sterilization methods (e.g., filtration, gamma irradiation) can compromise nanocarrier integrity. Storage conditions must maintain drug stability over shelf-life without aggregation or leakage.

D. Commercialization Hurdles

High development and manufacturing costs, coupled with complex regulatory approval, hinder commercialization. However, success stories like Doxil and Onivyde demonstrate that lipid-based carriers can reach the market with the right formulation and clinical strategy.[11,12]

X. CHALLENGES AND LIMITATIONS

A. Drug Leakage and Premature Release

Some lipid nanocarriers suffer from unstable drug encapsulation, especially under dilution or serum conditions, leading to reduced efficacy and increased side effects.

B. RES Clearance and Opsonization

The reticuloendothelial system (RES) rapidly clears foreign particles. Surface PEGylation can reduce opsonization, but long-term circulation may still result in immune recognition or complement activation.

C. Poor Tumor Penetration

Even with EPR effect-based targeting, deep penetration into dense solid tumors remains limited. Tumor heterogeneity, interstitial pressure, and stromal barriers all reduce therapeutic delivery.

D. Variability of the EPR Effect

The EPR effect is highly variable among tumor types, patient physiology, and tumor location, leading to **inconsistent outcomes** in clinical trials compared to animal studies.

E. Shelf Life and Storage

Lipid-based systems can be sensitive to temperature, light, and oxidation. Freeze-drying (lyophilization) is often needed but may affect redispersion and integrity.

XI. FUTURE DIRECTIONS AND PERSPECTIVES

A. Integration with Immunotherapy and Gene Therapy

Lipid nanocarriers can co-deliver anticancer drugs + siRNA/CRISPR constructs or immune modulators to stimulate anti-tumor immunity and overcome resistance.

B. AI and Machine Learning in Design

ML models are increasingly used to predict:

- Nanocarrier behavior based on composition
- Optimal particle size and surface charge
- Drug loading efficiencies
- Patient-specific response predictions

This enables data-driven formulation design and personalized delivery strategies.

C. Personalized Nanomedicine

Combining genomic profiling of patients with customizable lipid nanocarriers allows for tailored drug combinations, improving outcomes in precision oncology.

D. Combination Therapies

Co-delivery of multiple drugs (e.g., chemotherapy + anti-angiogenics) in one carrier can synergize action, reduce resistance, and simplify dosing regimens.

©IJRASET: All Rights are Reserved | SJ Impact Factor 7.538 | ISRA Journal Impact Factor 7.894 |

E. Smart and Programmable Nanocarriers


Future systems may feature:

- Self-regulating release systems responsive to multi-stimuli
- Logic-gated drug release (e.g., “AND” gates activated only under two conditions)
- Real-time feedback systems integrated with wearables or biosensors[13,14,15]

REFERENCES

[1] Morales, D. Eidinger, and A. W. Bruce, "Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors," J. Urol., vol. 116, pp. 180–182, 1976, doi: 10.1016/S0022-5347(17)58737-6.
[2] G. P. Dunn, A. T. Bruce, H. Ikeda, L. J. Old, and R. D. Schreiber, "Cancer immunoediting: from immunosurveillance to tumor escape," Nat. Immunol., vol. 3, pp. 991–998, 2002, doi: 10.1038/ni1102-991.
[3] S. A. Rosenberg et al., "Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer," N. Engl. J. Med., vol. 313, pp. 1485–1492, 1985, doi: 10.1056/NEJM198512053132327.
[4] C. Milstein, "The hybridoma revolution: an offshoot of basic research," BioEssays, vol. 21, pp. 966–973, 1999, doi: 10.1002/(SICI)1521-1878(199911)21:11<966::AID-BIES9>3.0.CO;2-Z.
[5] S. L. Topalian, C. G. Drake, and D. M. Pardoll, "Immune checkpoint blockade: a common denominator approach to cancer therapy," Cancer Cell, vol. 27, pp. 450–461, 2015, doi: 10.1016/j.ccell.2015.03.001.
[6] M. Sadelain, "CD19 CAR T cells," Cell, vol. 171, p. 1471, 2017, doi: 10.1016/j.cell.2017.12.002.
[7] F. Pastor et al., "An RNA toolbox for cancer immunotherapy," Nat. Rev. Drug Discov., vol. 17, pp. 751–767, 2018, doi: 10.1038/nrd.2018.132.
[8] M. L. Guevara, F. Persano, and S. Persano, "Advances in lipid nanoparticles for mRNA-based cancer immunotherapy," Front. Chem., vol. 8, p. 589959, 2020, doi: 10.3389/fchem.2020.589959.
[9] C. H. June, R. S. O’Connor, O. U. Kawalekar, S. Ghassemi, and M. C. Milone, "CAR T cell immunotherapy for human cancer," Science, vol. 359, pp. 1361–1365, 2018, doi: 10.1126/science.aar6711.
[10] X. Feng, W. Xu, Z. Li, W. Song, J. Ding, and X. Chen, "Immunomodulatory nanosystems," Adv. Sci., vol. 6, p. 1900101, 2019, doi: 10.1002/advs.201900101.
[11] L. Xu, X. Wang, Y. Liu, G. Yang, R. J. Falconer, and C.-X. Zhao, "Lipid nanoparticles for drug delivery," Adv. NanoBiomed Res., vol. 2, p. 2100109, 2022, doi: 10.1002/anbr.202100109.
[12] R. Tenchov, R. Bird, A. E. Curtze, and Q. Zhou, "Lipid nanoparticles─from liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement," ACS Nano, vol. 15, pp. 16982–17015, 2021, doi: 10.1021/acsnano.1c04996.
[13] M. J. Mitchell, M. M. Billingsley, R. M. Haley, M. E. Wechsler, N. A. Peppas, and R. Langer, "Engineering precision nanoparticles for drug delivery," Nat. Rev. Drug Discov., vol. 20, pp. 101–124, 2021, doi: 10.1038/s41573-020-0090-8.
[14] A. C. Anselmo and S. Mitragotri, "Nanoparticles in the clinic: An update," Bioeng. Transl. Med., vol. 4, p. e10143, 2019, doi: 10.1002/btm2.10143.
[15] M. J. Ostro, D. Giacomoni, D. Lavelle, W. Paxton, and S. Dray, "Evidence for translation of rabbit globin mRNA after liposome-mediated insertion into a human cell line," Nature, vol. 274, pp. 921–923, 1978, doi: 10.1038/274921a0.

©IJRASET: All Rights are Reserved | SJ Impact Factor 7.538 | ISRA Journal Impact Factor 7.894 |



10.22214/IJRASET

45.98

IMPACT FACTOR: 7.129

IMPACT FACTOR: 7.429

INTERNATIONAL JOURNAL FOR RESEARCH

IN APPLIED SCIENCE & ENGINEERING TECHNOLOGY

Call : 08813907089 (24*7 Support on Whatsapp)